mAb attack on WT1
Wilms tumor 1 is overexpressed in many different cancers, but most antibody and small molecule developers have deemed it undruggable because it is an intracellular transcription factor. Now, researchers at Eureka Therapeutics Inc. and the Memorial Sloan-Kettering Cancer Center have targeted Wilms tumor 1-positive cancer cells with a mAb against peptide fragments derived from the protein that are presented on the cells' surface.1
The biotech hopes to have the mAb in a Phase I trial in leukemia within two years and is seeking a clinical development partner.
Wilms tumor 1 (WT1) is a transcription factor found in the cell nucleus that is overexpressed in a range of leukemias and solid tumors. Ongoing efforts to address WT1-positive